AZN240927C80000
- 0.04
- 0.000.00%
AstraZeneca Newsroom
AstraZeneca's Market Position and Drug Pipeline Sustain Buy Rating Despite TB01 Trial Results
AstraZeneca: Strong Oncology Pipeline Fuels Growth and Outperformance – Buy Rating Endorsed
UBS Sticks to Its Sell Rating for AstraZeneca (AZN)
AstraZeneca Target Cut to 10500p From 11000p by Deutsche Bank
Kepler Capital Sticks to Their Hold Rating for AstraZeneca (AZN)
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $89
AstraZeneca Raised to Buy From Hold by Erste Group
AstraZeneca Analyst Ratings
Erste Group Upgrades AstraZeneca(AZN.US) to Buy Rating
AstraZeneca Buy Rating Affirmed: Anticipated FDA Approval of Dato and Long-Term Growth Potential
AstraZeneca's Promising NSCLC Treatment: A Buy Rating Amidst Breakthrough Developments
AstraZeneca (AZN) Receives a Buy From Barclays
BofA Securities Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $91.7
AstraZeneca's Promising Biomarker Data and Phase III Trials: Buy Rating Affirmed
Citi Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca: A Buy Rating on Anticipated Growth and Innovation Catalysts
Berenberg Bank Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $99
Berenberg Bank Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Reaffirms Their Buy Rating on AstraZeneca (AZN)
The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.